MoonLake announces completed submission of HS BLA to U.S. FDA for its nanobody Sonelokimab Post date September 30, 2026 ← MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
